TP53 mutation, NOTCH2 mutation, or 7q deletion — aggressive SMZL variant with shorter PFS...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-SMZL-HIGH-RISK-BIOLOGY`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-SPLENIC-MZL`
Sources	`SRC-ESMO-MZL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	TP53 mutation, NOTCH2 mutation, or 7q deletion — aggressive SMZL variant with shorter PFS; consider rituximab + bendamustine over rituximab monotherapy.
Clinical direction	intensify
Category	high-risk-biology

Trigger Logic

{
  "any_of": [
    {
      "finding": "tp53_mutation",
      "value": true
    },
    {
      "finding": "notch2_mutation",
      "value": true
    },
    {
      "finding": "del_7q",
      "value": true
    }
  ],
  "type": "biomarker"
}

Notes

Adverse molecular markers in SMZL are emerging branch points; combination therapy (BR) over monotherapy is supportive-care-tested but not yet hard standard.

Used By

No reverse references found in the YAML corpus.